<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432391</url>
  </required_header>
  <id_info>
    <org_study_id>16293</org_study_id>
    <nct_id>NCT02432391</nct_id>
  </id_info>
  <brief_title>Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations</brief_title>
  <official_title>Self-Monitoring of Blood Glucose (SMBG) as an Educational Tool and a Negative Feedback Loop to Reinforce Blood Glucose Lowering and Discourage Blood Glucose Elevating Self-Management Behaviors in Adults With T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>LifeScan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a lifestyle modification program (GEM) that&#xD;
      focuses on reducing after-meal blood glucose elevations can improve blood glucose control in&#xD;
      people with type 2 diabetes. Half of the participants will continue their routine medical&#xD;
      care, and half will receive five sessions of GEM in addition to their routine care. The two&#xD;
      groups will be assessed using diabetes-relevant medical, behavioral and psychological&#xD;
      measures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline glycosylated hemoglobin at 6 months</measure>
    <time_frame>0 and 6 months</time_frame>
    <description>HbA1c</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Routine Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants continue their routine medical care for type 2 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GEM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive the GEM (Glycemic load, Exercise, and Monitoring blood glucose) lifestyle modification program and continue their routine medical care for type 2 diabetes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>GEM</intervention_name>
    <description>GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.</description>
    <arm_group_label>GEM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with type 2 diabetes within the past 5 years&#xD;
&#xD;
          -  Age &gt;24 and &lt;80 years&#xD;
&#xD;
          -  HbA1c &gt;7.0%&#xD;
&#xD;
          -  Approval of primary care physician to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently using, or used within the last 3 months, medications that directly lower BG&#xD;
             (e.g., insulin, sulfonylureas, glinides, or DPP-4 inhibitors).&#xD;
&#xD;
          -  Currently using, or used within the last 3 months, thiazides at doses above HCTZ 25 mg&#xD;
             or equivalent, or loop diuretics above furosemide 20mg or equivalent.&#xD;
&#xD;
          -  Currently pregnant or contemplating pregnancy in the coming year&#xD;
&#xD;
          -  Currently using, or used within the last 3 months, medications that impede weight loss&#xD;
             (e.g., prednisone)&#xD;
&#xD;
          -  Having conditions that preclude increasing physical activity, e.g. severe neuropathy,&#xD;
             active cardiovascular disease, emphysema, osteoarthritis, stroke.&#xD;
&#xD;
          -  Undergoing cancer treatment&#xD;
&#xD;
          -  History of lactic acidosis&#xD;
&#xD;
          -  Diagnosed with renal impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cox, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>April 28, 2015</last_update_submitted>
  <last_update_submitted_qc>April 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Daniel Cox, PhD</investigator_full_name>
    <investigator_title>Professor, Department of Psychiatry and NB Sciences</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

